The submissions cover Chiesi’s Single Inhaler Triple Therapy (SITT, or ICS/LABA/LAMA) and its fixed-dose ICS/LABA combination, both delivered via pressurized metered-dose inhalers (pMDIs). The SITT application has gone to the European Medicines Agency under the EU centralized procedure, while the ICS/LABA application is going through a multi-country procedure with Germany’s BfArM as reference member state.

Both products are transitioning to HFA-152a, a next-generation propellant classified as non-PFAS and with low global warming potential.

“Our next-generation carbon minimal pMDIs provide the same level of care while reducing emissions by up to 90%,” says Andrea Bizzi, EVP Region Europe TOP 5 and Interim AIR Franchise at Chiesi.

For the Nordic market, Olav Fromm, General Manager, Chiesi Nordic, echoes the same message: “Our next-generation pMDI inhalers with a lower environmental footprint deliver the same efficacy, while significantly cutting emissions compared to today’s inhalers.”

The move builds on the UK MHRA’s approval in July 2026 of Chiesi’s beclometasone pMDIs formulated with HFA-152a, the first UK approval of the propellant in a pMDI. Inhaler propellants are the single largest source of Chiesi’s greenhouse gas emissions, and the HFA-152a transition is central to the company’s plan to reach net zero across its full value chain by 2035.